Po‐Jung Su
About
Po‐Jung Su is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Public Health, Environmental and Occupational Health.
According to data from OpenAlex, Po‐Jung Su has authored 47 papers receiving a total of 534 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Surgery, 17 papers in Pulmonary and Respiratory Medicine and 16 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Po‐Jung Su's work include Palliative Care and End-of-Life Issues (16 papers), Bladder and Urothelial Cancer Treatments (12 papers) and Urinary and Genital Oncology Studies (7 papers). Po‐Jung Su is often cited by papers focused on Palliative Care and End-of-Life Issues (16 papers), Bladder and Urothelial Cancer Treatments (12 papers) and Urinary and Genital Oncology Studies (7 papers). Po‐Jung Su collaborates with scholars based in Taiwan, United States and South Korea. Po‐Jung Su's co-authors include Wen‐Chi Chou, Jen‐Shi Chen, Chia‐Hsun Hsieh, Siew Tzuh Tang, Wen‐Cheng Chang, Yung‐Chang Lin, Jayashri Mahalingam, Chun‐Yen Lin, Ching‐Tai Huang and Yu‐Yi Chu and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Scientific Reports.
In The Last Decade
Po‐Jung Su
41 papers receiving 526 citations
Peers
Po‐Jung Su
Anthony Proietto Australia
Alyssa G. Rieber United States
Tomasz Banaś Poland
Mary Coerver- Connolly Ireland
Nicholas Zdenkowski Australia
Anke Rentsch Germany
Cécile Fortanier France
Catherine Bender United States
Rachel Yang United States
Benjamin Barnes Germany
Citations per year, relative to Po‐Jung Su Po‐Jung Su (= 1×)
peers
Anthony Proietto
Countries citing papers authored by Po‐Jung Su
Since
Specialization
Citations
This map shows the geographic impact of Po‐Jung Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Po‐Jung Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Po‐Jung Su more than expected).
Fields of papers citing papers by Po‐Jung Su
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Po‐Jung Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Po‐Jung Su. The network helps show where Po‐Jung Su may publish in the future.
Co-authorship network of co-authors of Po‐Jung Su
This figure shows the co-authorship network connecting the top 25 collaborators of Po‐Jung Su. A scholar is included among the top collaborators of Po‐Jung Su based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Po‐Jung Su. Po‐Jung Su is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Chou, Wen-Chi, Chia‐Hsun Hsieh, Ming‐Mo Hou, et al.. (2025). Validation of WHO 2017 Classification and Identification of Prognostic Factors in Patients with Pancreatic Neuroendocrine Neoplasms: A Real-World Experience in Taiwan. Journal of Cancer. 16(15). 4371–4377.
2.
Chen, Dong‐Yi, Ming‐Jer Hsieh, Tien‐Hsing Chen, et al.. (2025). Predicting Cardiovascular Risk in Patients with Prostate Cancer Receiving Abiraterone or Enzalutamide by Using Machine Learning. Cancers. 17(15). 2414–2414.
3.
Huang, Wen‐Kuan, Po‐Jung Su, Ming‐Jer Hsieh, et al.. (2025). Comparative effectiveness and safety of enzalutamide versus abiraterone in patients with metastatic castration-resistant prostate cancer: a nationwide registry-based cohort study from Taiwan. Journal of Cancer Research and Clinical Oncology. 151(11). 284–284.
4.
Cheng, Lijun, Po‐Jung Su, Ming‐Chun Kuo, et al.. (2024). Combining serum inflammatory markers and clinical factors to predict survival in metastatic urothelial carcinoma patients treated with immune checkpoint inhibitors. Therapeutic Advances in Medical Oncology. 16. 12749827–12749827.
5.
Huang, Shih‐Yu, Po‐Jung Su, C.-Y. Lin, et al.. (2024). The impact of body mass index on survival endpoints among patients with metastatic urothelial carcinoma undergoing treatment with immune checkpoint inhibitors: A real‐world multicenter analysis. Cancer Medicine. 13(2). e7008–e7008.
6.
Wen, Fur‐Hsing, Chia‐Hsun Hsieh, Po‐Jung Su, et al.. (2023). Factors Associated With Family Surrogate Decisional-Regret Trajectories. Journal of Pain and Symptom Management. 67(3). 223–232.e2.
7.
Wen, Fur‐Hsing, Chia‐Hsun Hsieh, Ming‐Mo Hou, et al.. (2023). Decisional-Regret Trajectories From End-of-Life Decision Making Through Bereavement. Journal of Pain and Symptom Management. 66(1). 44–53.e1.
8.
Wen, Fur‐Hsing, Chia‐Hsun Hsieh, Wen‐Chi Shen, et al.. (2023). Associations Between Surrogates’ Decisional Regret Trajectories and Bereavement Outcomes. Journal of the National Comprehensive Cancer Network. 21(11). 1141–1148.e2.
9.
Su, Po‐Jung, Ying Xiao, E.Q. Wu, et al.. (2023). A cost‐effectiveness analysis of avelumab plus best supportive care versus best supportive care alone as first‐line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma in Taiwan . Cancer Reports. 6(10). e1887–e1887.
10.
Tsai, Tsung‐Han, Po‐Jung Su, Shih‐Yu Huang, et al.. (2023). The prognostic significance of histologic variant on survival outcomes in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitor therapy. BMC Cancer. 23(1). 871–871.
11.
Kuo, Ming‐Chun, Po‐Jung Su, Chun‐Chieh Huang, et al.. (2020). Safety and Efficacy of Immune Checkpoint Inhibitors for Patients With Metastatic Urothelial Carcinoma and End-Stage Renal Disease: Experiences From Real-World Practice. Frontiers in Oncology. 10. 584834–584834.
12.
Wen, Fur‐Hsing, Jen‐Shi Chen, Po‐Jung Su, et al.. (2018). Terminally Ill Cancer Patients' Concordance Between Preferred Life-Sustaining Treatment States in Their Last Six Months of Life and Received Life-Sustaining Treatment States in Their Last Month: An Observational Study. Journal of Pain and Symptom Management. 56(4). 509–518.e3.
13.
Su, Po‐Jung, Min‐Hsien Wu, Hung‐Ming Wang, et al.. (2016). Circulating Tumour Cells as an Independent Prognostic Factor in Patients with Advanced Oesophageal Squamous Cell Carcinoma Undergoing Chemoradiotherapy. Scientific Reports. 6(1). 31423–31423.
14.
Mahalingam, Jayashri, Chun‐Yen Lin, Jy‐Ming Chiang, et al.. (2014). CD4+ T Cells Expressing Latency-Associated Peptide and Foxp3 Are an Activated Subgroup of Regulatory T Cells Enriched in Patients with Colorectal Cancer. PLoS ONE. 9(9). e108554–e108554.
15.
Chang, Wen‐Cheng, Wen‐Chi Chou, Po‐Jung Su, et al.. (2013). Longitudinal Changes and Predictors of Caregiving Burden While Providing End-of-Life Care for Terminally Ill Cancer Patients. Journal of Palliative Medicine. 16(6). 632–637.
16.
Kao, Chen‐Yi, Hung‐Ming Wang, Kuan‐Gen Huang, et al.. (2013). Predictive Factors For Do-Not-Resuscitate Designation Among Terminally Ill Cancer Patients Receiving Care From a Palliative Care Consultation Service. Journal of Pain and Symptom Management. 47(2). 271–282.
17.
Chou, Wen‐Chi, Yu‐Shin Hung, Chen‐Yi Kao, et al.. (2013). Impact of palliative care consultative service on disease awareness for patients with terminal cancer. Supportive Care in Cancer. 21(7). 1973–1981.
18.
Mahalingam, Jayashri, Yung‐Chang Lin, Jy‐Ming Chiang, et al.. (2012). LAP+CD4+ T Cells Are Suppressors Accumulated in the Tumor Sites and Associated with the Progression of Colorectal Cancer. Clinical Cancer Research. 18(19). 5224–5233.
19.
Kao, Chen‐Yi, Yu‐Shin Hung, Po‐Jung Su, et al.. (2012). Validation of a Palliative Prognostic Index to Predict Life Expectancy for Terminally Ill Cancer Patients in a Hospice Consultation Setting in Taiwan. Asian Pacific Journal of Cancer Prevention. 13(6). 2861–2866.
20.
Su, Po‐Jung, et al.. (2011). Leptomeningeal Carcinomatosis from a Primary Colon Cancer Patient. 27(3). 113–116.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Anthony Proietto Breakdown of academic impact, for papers by Alyssa G. Rieber Breakdown of academic impact, for papers by Tomasz Banaś Breakdown of academic impact, for papers by Mary Coerver- Connolly Breakdown of academic impact, for papers by Nicholas Zdenkowski Breakdown of academic impact, for papers by Anke Rentsch Breakdown of academic impact, for papers by Cécile Fortanier Breakdown of academic impact, for papers by Catherine Bender Breakdown of academic impact, for papers by Rachel Yang Breakdown of academic impact, for papers by Benjamin Barnes